DVAX vs. ACAD, ALKS, BOLT, CORT, GILD, LGND, MRK, FOLD, BCRX, and CLDX
Should you be buying Dynavax Technologies stock or one of its competitors? The main competitors of Dynavax Technologies include ACADIA Pharmaceuticals (ACAD), Alkermes (ALKS), Bolt Biotherapeutics (BOLT), Corcept Therapeutics (CORT), Gilead Sciences (GILD), Ligand Pharmaceuticals (LGND), Merck & Co., Inc. (MRK), Amicus Therapeutics (FOLD), BioCryst Pharmaceuticals (BCRX), and Celldex Therapeutics (CLDX). These companies are all part of the "medical" sector.
Dynavax Technologies vs. Its Competitors
Dynavax Technologies (NASDAQ:DVAX) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations and risk.
In the previous week, ACADIA Pharmaceuticals had 14 more articles in the media than Dynavax Technologies. MarketBeat recorded 19 mentions for ACADIA Pharmaceuticals and 5 mentions for Dynavax Technologies. Dynavax Technologies' average media sentiment score of 1.45 beat ACADIA Pharmaceuticals' score of 0.54 indicating that Dynavax Technologies is being referred to more favorably in the media.
ACADIA Pharmaceuticals has a net margin of 21.80% compared to Dynavax Technologies' net margin of -16.67%. ACADIA Pharmaceuticals' return on equity of 14.69% beat Dynavax Technologies' return on equity.
97.0% of Dynavax Technologies shares are held by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. 3.0% of Dynavax Technologies shares are held by insiders. Comparatively, 26.5% of ACADIA Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
ACADIA Pharmaceuticals has higher revenue and earnings than Dynavax Technologies. Dynavax Technologies is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Dynavax Technologies has a beta of 1.24, indicating that its stock price is 24% more volatile than the S&P 500. Comparatively, ACADIA Pharmaceuticals has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500.
Dynavax Technologies currently has a consensus target price of $24.33, indicating a potential upside of 140.21%. ACADIA Pharmaceuticals has a consensus target price of $28.88, indicating a potential upside of 12.27%. Given Dynavax Technologies' higher possible upside, research analysts plainly believe Dynavax Technologies is more favorable than ACADIA Pharmaceuticals.
Summary
ACADIA Pharmaceuticals beats Dynavax Technologies on 12 of the 17 factors compared between the two stocks.
Get Dynavax Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for DVAX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding DVAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Dynavax Technologies Competitors List
Related Companies and Tools
This page (NASDAQ:DVAX) was last updated on 9/3/2025 by MarketBeat.com Staff
Free DVAX Stock Alerts